InflaRx (IFRX) Net Cash Flow (QoQ) (2017 - 2026)
InflaRx (IFRX) Net Cash Flow (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.82% |
| Dec 31, 2025 | 247.60% |
| Sep 30, 2025 | 79.32% |
| Jun 30, 2025 | -214.32% |
| Mar 31, 2025 | 425.75% |
| Dec 31, 2024 | -216.84% |
| Sep 30, 2024 | 225.90% |
| Jun 30, 2024 | -151.65% |
| Mar 31, 2024 | 248.66% |
| Dec 31, 2023 | -497.62% |
| Sep 30, 2023 | -88.55% |
| Jun 30, 2023 | 227.38% |
| Mar 31, 2023 | -1,134.50% |
| Dec 31, 2022 | -169.78% |
| Sep 30, 2022 | 106.20% |
| Jun 30, 2022 | -286.32% |
| Mar 31, 2022 | 129.22% |
| Dec 31, 2021 | -11,206.87% |
| Sep 30, 2021 | 95.68% |
| Jun 30, 2021 | -117.51% |